Pesquero J B, Boschcov P, Lindsey C J, Paiva A C
Department of Biophysics, Paulista School of Medicine, São Paulo, Brazil.
J Hypertens. 1992 Dec;10(12):1479-84. doi: 10.1097/00004872-199210120-00007.
To examine the metabolism of kinins and angiotensin I in the pulmonary circulation of spontaneously hypertensive rats (SHR) and normotensive Wistar rats (NWR).
Bradykinin inactivation was estimated in vivo by comparison of the hypotensive effect of intra-arterial and intravenous injections, and in the in situ perfused lung by analysing the breakdown products using high-performance liquid chromatography.
In vivo pulmonary degradation of bradykinin, but not that of higher homologues of this peptide, was shown to be significantly greater in SHR. Angiotensin I converting activity was found to be increased in lungs of SHR. The recovery of bradykinin and homologues from perfused SHR lung was decreased relative to NWR. Des-(Phe-Arg) fragments of all kinin analogues were identified in the pulmonary perfusates. When bradykinin and des-Arg9-bradykinin were injected in the perfused lungs, the respective fragments 4-9 and 4-8 were also identified in the perfusates. When kininase II was inhibited with enalaprilat, the recovery of bradykinin increased from 10 to 43% in SHR and from 23 to 58% in NWR, whereas about 90% of the higher bradykinin homologues were recovered in both SHR and NWR. Aminopeptidase P and dipeptidylaminopeptidase IV, as measured by the recovery of fragment 4-9 under kininase II inhibition, accounted for about 40% of the total pulmonary kininase activity in the SHR lungs and 25% of that of the NWR lungs.
The results show that SHR have increased kininase and angiotensin converting activity compared with NWR, and that kinins as well as angiotensin may contribute to the pathogenesis of hypertension. Aminopeptidase P and dipeptidylaminopeptidase IV may contribute to the increased in vivo degradation of bradykinin observed in the SHR.
研究自发性高血压大鼠(SHR)和正常血压的Wistar大鼠(NWR)肺循环中激肽和血管紧张素I的代谢情况。
通过比较动脉内和静脉内注射的降压效果在体内评估缓激肽失活情况,并通过高效液相色谱分析降解产物在原位灌注肺中评估缓激肽失活情况。
结果显示,SHR体内缓激肽的肺降解显著高于该肽的高级同系物。发现SHR肺中的血管紧张素I转换活性增加。相对于NWR,灌注的SHR肺中缓激肽和同系物的回收率降低。在肺灌注液中鉴定出所有激肽类似物的去(苯丙氨酸 - 精氨酸)片段。当在灌注肺中注射缓激肽和去 - 精氨酸9 - 缓激肽时,在灌注液中也鉴定出各自的4 - 9和4 - 8片段。当用依那普利拉抑制激肽酶II时,SHR中缓激肽的回收率从10%增加到43%,NWR中从23%增加到58%,而在SHR和NWR中约90%的高级缓激肽同系物被回收。通过在激肽酶II抑制下片段4 - 9的回收率测定,氨肽酶P和二肽基氨基肽酶IV分别占SHR肺中总肺激肽酶活性的约40%和NWR肺中总肺激肽酶活性的25%。
结果表明,与NWR相比,SHR的激肽酶和血管紧张素转换活性增加,激肽以及血管紧张素可能参与高血压的发病机制。氨肽酶P和二肽基氨基肽酶IV可能导致SHR中观察到的缓激肽体内降解增加。